Daiichi Sankyo and Merck's New Drug Trial Faces Major Concerns, 586 Late-Stage Lung Cancer Patients Encounter New Challenges!

On Tuesday, Daiichi Sankyo (4568.T) and Merck & Co (MRK.N) announced that its drug patritumab deruxtecan achieved its main goal in a clinical trial in advanced patients, extending the period of disease-free progression in some lung cancer patients. The study, which involved 586 patients, was designed to evaluate the drug's chemotherapy effect on patients with non-small cell lung cancer (NSCLC) who carry a specific genetic mutation. The therapy is one of three antibody to drug conjugators (ADCs) included in a $22 billion joint development and commercialization agreement signed last year between Merck and Daiichi Sankyo. ADC is a targeted cancer therapy that combines monoclonal antibodies with cell-killing toxins to precisely strike tumor cells while minimizing damage to healthy cells. In the current study, the drug was targeted at patients who had previously been treated with tyrosine kinase inhibitors (TKI), a type of drug that targets mutations in specific proteins that inhibit abnormal cell growth. Although TKI has made significant advances in the field of cancer treatment, transforming many otherwise untreatable cases into manageable states, patients can become resistant to treatment or experience intolerable side effects, requiring other treatment options. The companies said they plan to present the trial data at an upcoming medical conference and communicate with global regulators to explore next steps. At a camp for flood victims in Nigeria's Borno state, Bintu Amadu waits for hours with hundreds of other displaced people to see a doctor. It is estimated that non-small cell lung cancer accounts for approximately 85% of lung cancer cases worldwide, with specific genetic mutations present in 14% to 38% of tumors.